Ascendis Pharma Revenue vs. Price To Earning

ASND Stock  USD 129.67  2.75  2.08%   
Based on the key profitability measurements obtained from Ascendis Pharma's financial statements, Ascendis Pharma AS may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Ascendis Pharma's ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2013-12-31
Previous Quarter
36 M
Current Value
57.8 M
Quarterly Volatility
20.2 M
 
Yuan Drop
 
Covid
At present, Ascendis Pharma's Days Of Sales Outstanding is projected to decrease significantly based on the last few years of reporting. At present, Ascendis Pharma's Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Change To Netincome is expected to grow to about 106.4 M, whereas Operating Income is projected to grow to (432.8 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.570.8336
Way Down
Slightly volatile
For Ascendis Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ascendis Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ascendis Pharma AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ascendis Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ascendis Pharma AS over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.87)
Revenue Per Share
5.595
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.28)
Return On Equity
(8.18)
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Ascendis Pharma AS Price To Earning vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Ascendis Pharma's current stock value. Our valuation model uses many indicators to compare Ascendis Pharma value to that of its competitors to determine the firm's financial worth.
Ascendis Pharma AS is rated fifth in revenue category among its peers. It is rated below average in price to earning category among its peers . At present, Ascendis Pharma's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Ascendis Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Ascendis Revenue vs. Competition

Ascendis Pharma AS is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 6.21 Billion. Ascendis Pharma holds roughly 266.72 Million in revenue claiming about 4% of equities under Health Care industry.

Ascendis Price To Earning vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Ascendis Pharma

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
266.72 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Ascendis Pharma

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(9.10) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Ascendis Price To Earning Comparison

Ascendis Pharma is currently under evaluation in price to earning category among its peers.

Ascendis Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Ascendis Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ascendis Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Ascendis Pharma's change in net profit over the period of time. It can combine multiple indicators of Ascendis Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-153.4 M-145.8 M
Operating Income-455.5 M-432.8 M
Income Before Tax-474.1 M-450.4 M
Total Other Income Expense Net-18.6 M-17.7 M
Net Loss-481.4 M-457.4 M
Income Tax Expense7.3 M7.7 M
Net Loss-481.4 M-457.4 M
Net Loss-524.9 M-498.6 M
Interest Income16.9 M17.7 M
Net Interest Income-27.2 M-25.8 M
Change To Netincome101.4 M106.4 M
Net Loss(8.55)(8.98)
Income Quality 0.97  0.75 
Net Income Per E B T 1.02  0.78 

Ascendis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Ascendis Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ascendis Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ascendis Pharma's important profitability drivers and their relationship over time.

Use Ascendis Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ascendis Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascendis Pharma will appreciate offsetting losses from the drop in the long position's value.

Ascendis Pharma Pair Trading

Ascendis Pharma AS Pair Trading Analysis

The ability to find closely correlated positions to Ascendis Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ascendis Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ascendis Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ascendis Pharma AS to buy it.
The correlation of Ascendis Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ascendis Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ascendis Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ascendis Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Ascendis Pharma position

In addition to having Ascendis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Municipals ETFs Thematic Idea Now

Broad Municipals ETFs
Broad Municipals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Municipals ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Municipals ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
Check out Trending Equities.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
To fully project Ascendis Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ascendis Pharma AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ascendis Pharma's income statement, its balance sheet, and the statement of cash flows.
Potential Ascendis Pharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Ascendis Pharma investors may work on each financial statement separately, they are all related. The changes in Ascendis Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ascendis Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.